Toxicogenomics and Predictive Toxicology Laboratory, Systems Toxicology and Health Risk Assessment Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31, Mahatma Gandhi Marg, Lucknow 226 001, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, Uttar Pradesh, India.
Toxicogenomics and Predictive Toxicology Laboratory, Systems Toxicology and Health Risk Assessment Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31, Mahatma Gandhi Marg, Lucknow 226 001, Uttar Pradesh, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201 002, Uttar Pradesh, India.
Ageing Res Rev. 2022 Nov;81:101727. doi: 10.1016/j.arr.2022.101727. Epub 2022 Aug 28.
About 10% of the adult population is living with type 2 diabetes mellitus (T2DM) and 1% of the population over 60 years of age is suffering from Parkinson's disease (PD). A school of thought firmly believes that T2DM, an age-related disease, augments PD risk. Such relationship is reflected from the severity of PD symptoms in drug naive subjects possessing T2DM. Onset of Parkinsonian feature in case controls possessing T2DM corroborates the role of hyperglycemia in PD. A few cohort, meta-analysis and animal studies have shown an increased PD risk owing to insulin resistance. High fat diet and role of insulin signaling in the regulation of sugar metabolism, oxidative stress, α-synuclein aggregation and accumulation, inflammatory response and mitochondrial function in PD models and sporadic PD further connect the two. Although little is reported about the implication of PD in hyperglycemia and T2DM, a few studies have also contradicted. Ameliorative effect of anti-diabetic drugs on Parkinsonian symptoms and vague outcome of anti-PD medications in T2DM patients also suggest a link. The article reviews the literature supporting augmented risk of one by the other, analysis of proof of the concept, facts, challenges, future possibilities and standpoint on the subject.
大约 10%的成年人患有 2 型糖尿病（T2DM），1%的 60 岁以上人口患有帕金森病（PD）。有一种观点坚信，T2DM 是一种与年龄相关的疾病，会增加 PD 的风险。这种关系反映在未经药物治疗的患有 T2DM 的受试者中 PD 症状的严重程度上。在患有 T2DM 的病例对照中帕金森特征的出现证实了高血糖在 PD 中的作用。一些队列研究、荟萃分析和动物研究表明，由于胰岛素抵抗，PD 的风险增加。高脂肪饮食和胰岛素信号在调节糖代谢、氧化应激、α-突触核蛋白聚集和积累、炎症反应和线粒体功能中的作用在 PD 模型和散发性 PD 中进一步联系在一起。虽然关于 PD 在高血糖和 T2DM 中的意义的报道很少，但也有一些研究对此提出了质疑。抗糖尿病药物对帕金森病症状的改善作用和抗 PD 药物在 T2DM 患者中的模糊疗效也表明存在联系。本文综述了支持一种疾病增加另一种疾病风险的文献，分析了概念验证的证据、事实、挑战、未来可能性以及对该主题的立场。
